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Abstract
Background—The reasons for increasing rates of bilateral mastectomy for unilateral breast 
cancer are incompletely understood and associations of disease stage with bilateral surgery have 
been inconsistent. We examined associations of clinical and sociodemographic factors, including 
stage, with surgery type and reconstruction receipt among women with breast cancer.
Patients/Methods—We surveyed a diverse population-based sample of women from northern 
California cancer registries with stage 0–III breast cancer diagnosed during 2010–2011 
(participation rate=68.5%). Using multinomial logistic regression, we examined factors associated 
with bilateral and unilateral mastectomy (vs. breast conservation [BCS]), adjusting for tumor and 
sociodemographic characteristics. In a second model, we examined factors associated with 
reconstruction for mastectomy-treated patients.
Results—Among 487 participants, 58% had BCS, 32% had unilateral mastectomy, and 10% 
underwent bilateral mastectomy. In adjusted analyses, women with stage III (vs. stage 0) cancers 
had higher odds of bilateral mastectomy (odds ratio [O.R]=8.28; 95% Confidence Interval=2.32–
29.50); women with stage II and III (vs. stage 0) disease had higher odds of unilateral mastectomy. 
Higher (vs. lower) income was also associated with bilateral mastectomy, while age ≥60 (vs. <50) 
was associated with lower odds of bilateral surgery. Among mastectomy-treated patients (n=206), 
bilateral mastectomy, unmarried status, higher education and income were all associated with 
reconstruction (Ps<0.05).
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Conclusion—In this population-based cohort, women with the greatest risk of distant recurrence 
were most likely to undergo bilateral mastectomy despite a lack of clear medical benefit, raising 
concern for over-treatment. Our findings highlight the need for interventions to assure women are 
making informed surgical decisions.
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INTRODUCTION
Rates of mastectomy and contralateral mastectomy for patients with cancer are on the 
rise1–11 despite strong evidence of equivalent long-term survival for breast preservation 
(BCS) and mastectomy,12, 13 international consensus for BCS as the preferred therapy when 
possible,14, 15 and initial increasing frequency of BCS following consensus statements.1, 2 
Although the reasons for higher rates of unilateral and bilateral mastectomy are 
incompletely understood, younger patient age, peace of mind, higher socioeconomic status 
(SES), white race, regional variation, preoperative magnetic resonance imaging (MRI), 
family history/genetics, celebrity/media impact, and cosmetic concerns/symmetry have been 
associated with bilateral mastectomy.5–11, 16–30 Past studies have varied in their sample size, 
geographic coverage, and information about reconstruction; they are also frequently registry-
based and lacking individualized information on socio-demographic factors. Past studies 
have also had inconsistent findings for receipt of bilateral surgery by stage, and are limited 
by use of older data.9, 10, 29 Understanding how disease stage may impact surgical decision 
making may provide important information on how to best frame discussions with patients 
around risks and benefits of local therapy options.
In this study, we surveyed a diverse sample of women with breast cancer diagnosed in 2010–
2011 in northern California about their cancer treatment. We examined patient clinical and 
sociodemographic factors associated with receipt of unilateral and bilateral mastectomy as 
well as reconstruction for mastectomy-treated patients.
METHODS
Study Population
As previously described31 we identified 1,118 white, black, or Hispanic women from 
Regions 1/8 (San Francisco/Santa Clara) and Region 3 (Sacramento) of the California 
Cancer Registry (CCR) who were diagnosed with stage 0-III breast cancer during 2010–
2011. The study was approved by the CCR, the California Health and Human Services 
Agency Committee for the Protection of Human Subjects, and Harvard Medical School’s 
Committee on Human Studies.
Survey Administration and Patient Enrollment
We mailed letters to eligible patients in English and Spanish inviting them to participate in a 
survey about their breast cancer care. Potential participants were interviewed by phone after 
providing verbal informed consent. Interviews were administered in English or Spanish by 
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trained study staff using computer assisted telephone interview software; seventy of 136 
Hispanic women were interviewed in Spanish. Participants received $20 upon interview 
completion.
Survey
Participants were asked general questions about their breast cancer diagnosis and treatment 
and also reported race/ethnicity, educational attainment,32 insurance coverage at diagnosis,32 
health literacy,33 and comorbidity.32, 34 We obtained tumor and treatment information from 
the CCR, including surgical type and cancer stage. The survey instrument was published 
previously.35
Survey Response Rates
As shown in Figure 1, among 1,118 patients, 231 refused participation (30 sent opt out card, 
201 refused by phone), 317 could not be reached (227 no valid contact information, 90 could 
not be contacted after 6 attempts), and 68 were deceased/too ill; 502 women responded, for 
an American Association for a Public Opinion Research36 response rate of 47.8%. The 
participation rate among those for whom we had contact information was 68.5%. 
Respondents had similar baseline demographic and tumor characteristics as non-
respondents, except respondents were younger (mean age=58 vs. 64; p<.0001). Because our 
survey focused on care for white, black, and Hispanic patients, two women who self-
identified as Asian were excluded. We excluded 13 women whose type of cancer-directed 
surgery was coded as unknown, not otherwise specified (NOS), not done, or local tumor 
destruction according to the CCR. The final analytic cohort included 487 women, all of 
whom had unilateral cancers according to the CCR. Interviews for the 502 women were 
conducted between 1/17/02 and 12/3/13 with a mean time from diagnosis to interview of 2.4 
years (range 0.2–4.7 years).
Variables of Interest
The outcome of interest was the type of surgery received as defined by the CCR. We 
categorized surgery as (1) BCS (partial mastectomy, less than total mastectomy, lumpectomy 
or excisional biopsy, re-excision of biopsy site, segmental mastectomy), (2) unilateral 
mastectomy with reconstruction (total [simple] mastectomy, modified radical mastectomy 
[MRM], or radical mastectomy all either with reconstruction, tissue, implant, or combined 
tissue/implant and without removal of the contralateral breast), (3) unilateral mastectomy 
without reconstruction (subcutaneous mastectomy, total [simple] mastectomy MRM, radical 
mastectomy, extended radical mastectomy all without reconstruction or removal of 
contralateral breast, (4) bilateral mastectomy with reconstruction (total [simple] mastectomy 
or MRM with removal of contralateral breast, all with reconstruction, tissue, implant, or 
combined tissue/implant), and (5) bilateral mastectomy without reconstruction. We 
examined receipt of BCS, unilateral mastectomy, and bilateral mastectomy (regardless of 
reconstruction). We also assessed reconstruction among women who underwent bilateral or 
unilateral mastectomy.
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We defined American Joint Commission on Cancer, 6th edition stage using CCR data. 
Control variables of interest were selected a priori based on clinical relevance to surgery 
selection and/or previously reported associations with bilateral surgery and were categorized 
as per Table 1. These variables included self-reported race/ethnicity, age, marital status, 
insurance status at diagnosis, number of comorbidities32, 34 (prior other cancer, diabetes, 
heart disease, stroke, chronic lung disease, kidney problem, depression/psychiatric 
problems), educational attainment, household income over the last year, and mean health 
literacy score.33
Statistical Analysis
We used χ2 tests to assess differences in surgical procedures by baseline characteristics, and 
Kruskal Wallis tests to assess differences by mean health literacy scores. We used 
multinomial logistic regression to assess the probability of having unilateral or bilateral 
mastectomy versus BCS, adjusting for the control variables listed above.
In a second model, we used logistic regression to examine receipt of reconstruction among 
mastectomy-treated patients (n=206), adjusting for the same variables listed above and also 
including a variable for bilateral (vs. unilateral) mastectomy.
RESULTS
Baseline characteristics
Baseline characteristics by surgery type for the 487 participants are shown in Table 1. Most 
women underwent BCS (58%), 32% underwent unilateral mastectomy, and 10% had 
bilateral mastectomy. Figure 2 shows surgery type and whether reconstruction was 
performed. Among the 206 mastectomy-treated patients, 25% had bilateral mastectomy and 
27% of all mastectomy-treated women underwent reconstruction. For those who underwent 
unilateral mastectomy (n=155), 28 (18%) had reconstruction while 27 of the 51 patients 
(53%) having bilateral mastectomy had reconstruction.
Unadjusted results for surgery type
In unadjusted results (Table 1), more advanced stage was associated with higher rates of 
both unilateral and bilateral mastectomy, with 74% of women with stage III disease 
undergoing these procedures. Among mastectomy-treated patients with stage III disease, 
29% had bilateral mastectomy. Hispanic patients had the highest rates of BCS (61%), blacks 
had the highest rates of unilateral mastectomy (38%), and whites had the highest rates of 
bilateral surgery (15%, p=0.028). Patients aged <50 had higher rates of bilateral surgery than 
other age groups (18% vs. 6% in women ages ≥60, p=0.012) and those with higher 
educational attainment and household income also had more bilateral surgery than women of 
lower SES, who had higher rates of unilateral mastectomy than other groups. The 
differences in procedures by income were primarily observed among those undergoing 
mastectomy (i.e. unilateral vs. bilateral surgery), with relatively equal numbers of women 
undergoing BCS across income groups (56–60%).
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Adjusted results for surgery type
In adjusted analyses (Table 2), stage II disease (vs. 0) was statistically significantly 
associated with higher odds for unilateral (OR=2.21, 95% CI=1.19–4.11) but not bilateral 
mastectomy (OR=2.48, 95% CI=0.88–6.96) and stage III disease (vs. 0) was strongly 
associated with both unilateral (OR=5.31, 95% CI=2.20–12.80) and bilateral (OR=8.28, 
95% CI=2.32–29.50) mastectomy. We also observed lower odds of bilateral surgery for 
women aged ≥60 ([adjusted odds ratio] OR=0.35, 95% Confidence Interval [CI]=0.15–0.84 
vs. ages <50]) and higher odds of bilateral surgery for women with household incomes ≥
$60,000/year (vs. incomes <$20,000/year; OR=5.19, 95% CI=1.18–22.82).
Reconstruction
In models examining receipt of reconstruction among 206 mastectomy-treated patients 
(Table 2), women who were unmarried (vs. married, OR=1.37, 95% CI=1.37–10.06), 
college graduates (vs. high school, OR=4.33, 95% CI=1.37–13.71), had higher income (vs. 
<$20,000, OR=7.89, 95% CI=1.35–46.12 for $20,000–39,999; OR=9.86, 95% CI=1.34–
72.83 for $40,000–59,999; OR=14.95, 95% CI=2.11–105.88 for ≥$60,000) and had bilateral 
(vs. unilateral, OR=3.53, 95% CI=1.52–8.18) mastectomy were more likely to have 
reconstruction. Stage was not significantly associated with reconstruction.
DISCUSSION
Rates of bilateral mastectomy for unilateral breast cancer have been increasing in recent 
years despite consistent evidence that this procedure does not improve long term outcomes 
for most patients8, 37, 38 and may lead to long term issues with body image.39, 40 In a large, 
diverse and modern cohort of breast cancer patients, we observed relatively high rates of 
bilateral mastectomy for women with unilateral, stage 0-III breast cancers: 10% underwent 
bilateral mastectomy and 25% of all patients undergoing mastectomy had bilateral surgery. 
Approximately 18% of women had reconstruction for unilateral mastectomy, whereas nearly 
53% of patients with bilateral mastectomy had reconstruction. For women with stage III 
disease, the rates of bilateral mastectomy among mastectomy-treated patients was even 
higher than the overall sample, with 29% having bilateral surgery. Prior studies have 
reported rates of bilateral mastectomy ranging from 3–30%, 8, 9, 18, 19 and likely differ due 
to differences in settings (i.e. single institution, population-based, hospital-based), ages of 
women included, and the time periods analyzed. In addition, direct comparisons of surgical 
procedures across studies are limited by differences in the surgical outcomes of interest, with 
some studies examining bilateral mastectomy for those who undergo mastectomy only while 
other studies compare all procedures separately. Consistent with prior work, we observed 
higher rates of bilateral mastectomy for young women, white women, and those with higher 
income7, 10 and strong associations for reconstruction with higher educational attainment 
and annual income.41–43
We also noted strong associations for bilateral surgery with stage III (vs. stage 0) disease, 
which has been less consistently observed by others. For example, Yao et al.10 and Ashfaq et 
al.29 reported lower odds of bilateral surgery with increasing stage and Tuttle et al.9 
observed higher rates of bilateral surgery for stage III vs. I disease; several other papers have 
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shown no association of stage with bilateral mastectomy. Our findings for stage are similar 
to the Tuttle findings but are in a more recent population-based cohort. The higher rates of 
bilateral mastectomy among stage III patients with unilateral breast cancer are surprising 
given the well documented lack of survival advantage for bilateral surgery.8, 37, 38 
Furthermore, patients with higher-stage disease may be least likely to benefit from 
contralateral breast surgery because their greatest risk is distant recurrence rather than new, 
contralateral disease, in contrast to the negligible competing systemic recurrence risks for 
patients with DCIS. This finding may be explained by women with higher-risk disease 
wishing to be as ‘aggressive’ as possible to eliminate future risk or having more anxiety-
driven decisions.26, 30 It may also derive from a desire to avoid ever again going through the 
aggressive systemic treatment they need for their higher risk index cancer.26 Past research 
suggests that even though women may know that bilateral mastectomy will not improve 
survival across populations, they cite improvement in survival as a reason for choosing 
bilateral surgery,26 suggesting a possible disconnect in processing the facts and emotions 
surrounding surgical decision-making. Patients should be counseled about these issues 
during the decision-making process, with conversations tailored to an individual’s potential 
risk and benefit of bilateral surgery, particularly for those with who have a higher risk for 
distant recurrence.
An alternate explanation for our finding of higher rates of bilateral mastectomy among stage 
III patients may be related to improved reconstructive options and insurance coverage for 
reconstructive procedures in recent years, making bilateral mastectomy followed by 
reconstruction more appealing than unilateral mastectomy, and essentially replacing the 
unilateral mastectomy option for some women.5, 29 In other words, if a woman requires a 
mastectomy or chooses mastectomy for a higher-risk tumor, she is more likely to consider 
contralateral surgery than a woman undergoing BCS. The higher odds of reconstruction we 
observed for women undergoing bilateral (vs. unilateral) mastectomy are consistent with this 
hypothesis.
Our results add to the literature supporting a need to better understand the breast surgery 
decision-making process and to design interventions in this area. Patients considering 
bilateral surgery should be counseled about the additional risks associated with more 
aggressive surgical procedures,44–46 the burdens of multi-stage surgeries required during the 
reconstructive process, the potential impact on sexuality and body image,39, 40 and the lack 
of clear medical benefits for most patients.8, 37, 38 Recent evidence showing higher rates of 
BCS for women seen in a multidisciplinary setting (vs. individual providers) suggests that a 
team of providers may reduce the number of women receiving bilateral mastectomy.47 
Decision tools may also be effective interventions;48 large-scale studies examining the utility 
of such tools are underway. Insurers are now playing a larger role in these decisions as well; 
some payers have restricted coverage for bilateral mastectomy to women with a clear 
‘medical necessity’ (e.g. a known genetic mutation or history of chest irradiation, who have 
markedly increased risk for contralateral cancers).49–51 In a climate where reducing health 
care costs is increasingly important, more insurers may impose similar restrictions.
We recognize several study limitations. First, we lacked information on patient preferences, 
genetic testing results, family history, provider recommendations, surgical options provided 
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to patients, and whether patients met with a plastic surgeon. Second, surveyed patients 
resided in northern California only and may not be generalizable to other regions. 
Furthermore, regional and institutional variation in availability of plastic surgeons and 
differing care styles are well documented and may not be well represented in this study 
where many women were treated in two large hospital systems.5, 41, 52, 53 Third, although 
registry data have been demonstrated to accurately capture surgical treatments,54 it is 
possible that some procedures were miscoded or missed because they were completed long 
after a patient’s diagnosis (i.e. delayed reconstruction occurring more than a year after 
diagnosis). Nevertheless, our survey included a large and diverse, recently diagnosed 
population-based sample of women with individual information on SES, health literacy, 
insurance, and reconstruction, allowing for exploration of these important outcomes.
In conclusion, we observed relatively high rates of bilateral mastectomy for women with 
stage 0-III breast cancer. Among other previously described factors associated with bilateral 
mastectomy, stage III disease was significantly associated with bilateral mastectomy. Given 
the lack of medical benefits for contralateral surgery, these findings highlight the need for 
enhanced discussions and decision tools during the surgical decision-making process, and 
particularly for women with higher-stage cancers.
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Rates of bilateral mastectomy for unilateral breast cancer are increasing nationwide and 
the reasons for this are incompletely understood. Past associations of disease stage with 
receipt of bilateral surgery for unilateral cancers are inconsistent. We surveyed a diverse 
sample of 483 women in northern California registries and examined factors associated 
with receipt of unilateral and bilateral mastectomy compared with breast conversation 
(BCS), including disease stage. In this cohort, 10% of women underwent bilateral 
mastectomy, 58% had BCS, and 32% had unilateral mastectomy. In adjusted analyses, 
among other factors previously reported to be associated with bilateral mastectomy, we 
noted significantly higher odds of bilateral mastectomy for stage III (vs. stage 0) cancers. 
This raises concern for over-treatment given that most women will not derive a clear 
medical benefit with bilateral mastectomy. Our findings highlight the need for 
interventions to assure women are making informed surgical decisions.
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Figure 1. Schema for study enrollment
American Association for a Public Opinion Research (AAPOR) Response Rate36 = 502/
(1118-68) = 47.8% Participation Rate = 502/(1118-68-317) = 68.5%
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Figure 2. Proportion of patients who underwent each type of surgery, including reconstruction a
a Note, because of rounding, the total percentage of women undergoing bilateral mastectomy 
is 10%
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Table 1











n (%) n (%) n (%)
Stagec <0.0001
   0 [n=86] 59 (69) 21 (24) 6 (7)
   I [n=198] 134 (68) 49 (25) 15 (8)
   II [n=157] 76 (48) 61 (39) 20 (13)
   III [n=46] 12 (26) 24 (52) 10 (22)
Race/ethnicity 0.028
   Non-Hispanic white [n=220] 126 (57) 61 (28) 33 (15)
   Non-Hispanic black [n=132] 73 (55) 50 (38) 9 (7)
   Hispanic [n=135] 82 (61) 44 (33) 9 (7)
Age (years) 0.012
   <50 [n=124] 60 (48) 42 (34) 22 (18)
   50–59 [n=152] 90 (59) 46 (30) 16 (11)
   60+ [n=211] 131 (62) 67 (32) 13 (6)
Marital status 0.109
   Married [n=277] 154 (56) 87 (31) 36 (13)
   Unmarried/unknown [n=210] 127 (60) 68 (32) 15 (7)
Comorbidity score d 0.884
   0 [n=195] 112 (58) 62 (32) 21 (11)
   1 [n=178] 101 (57) 56 (31) 21 (12)
   2+ [n=114] 68 (60) 37 (32) 9 (8)
Educational attainment 0.018
   High school or less [n=163] 89 (55) 63 (39) 11 (7)
   Some college [n=153] 96 (63) 44 (29) 13 (9)
   College graduate [n=171] 96 (56) 48 (28) 27 (16)
Household Income 0.002
   <$20,000 [n=97] 55 (57) 38 (39) 4 (4)
   $20,000-$39,999 [n=89] 51 (57) 33 (37) 5 (6)
   $40,000-$59,999 [n=73] 44 (60) 22 (30) 7 (10)
   ≥$60,000 [n=178] 100 (56) 45 (25) 33 (19)
   Don’t know [n=50] 31 (62) 17 (34) 2 (4)
Insurance at diagnosis 0.148
   Yes [n=460] 270 (59) 142 (31) 48 (10)
























n (%) n (%) n (%)
   No [n=27] 11 (41) 13 (48) 3 (11)
Average health literacy scoree (SD) 1.80 (1.07) 1.82 (1.02) 1.57 (1.00) 0.293
Abbreviations: SD=standard deviation
a
With or without reconstruction
b
Using chi-square tests for categorical variables and the Kruskal-Wallis test for the health literacy score; bolded results are significant with P<0.05
c
Using cancer registry data; one case reported as stage IV was categorized as stage III
d
Comorbidity was assessed by adding the number of self-reported medical conditions32, 34 including other cancers, diabetes, heart attack, stroke, 
emphysema/chronic bronchitis/asthma/other chronic lung disease, kidney problems, depression/other psychiatric illness.
e
Health literacy was defined using a validated, 3-item screening tool:33 (1) “How confident are you filling out medical forms,” (2) “How often do 
you have problems learning about your medical condition?,” and (3) “How often do you have someone help you read hospital materials?” 
Responses used a 5-item Likert scale. After reversing responses for the first item, we assigned each answer a score of 1–5 (lower numbers reflect 
most confidence/fewest problems) and averaged the three scores. Lower scores indicate better literacy.
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